| 英文别名 |
17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE;BIMATOPROST;BIMATOPROST(TM);LUMIGAN;N-ETHYL-9ALPHA,11ALPHA,15S-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROSTA-5Z, 13E-DIEN-1-AMIDE;BIMATOPROST(LUMIGAN);17-phenyl-tri-norprostaglandin f2α-ethyl amide;(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide;(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide;Prostamide;C25H37NO4;17-phenyl trinor Prostaglandin F2α ethyl amide;AGN 192024;Bimatoprost (17-Phenyl-tri-norprostaglandin F2α-ethyl amide);BiMapnost;BiMatoprost HOUSE STANDARD;Bimatoprost API;cGMP Bimatoprost;Bimatoprost, >=99.5%;(15R)-BiMatoprost;(Z)-7-[(1S,2S,3R,5R)-3,5-Dihydroxy-2-[(E)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-e;(Z)-7-[(1S,2S,3R,5R)-3,5-Dihydroxy-2-[(E)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide;DURYSTA;DURYSTA;(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide;(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide;(5z)-7-{(1r,2r,3r,5s)-3,5-Dihydroxy-2-[(1e,3s)-3-Hydroxy-5-Phenylpent-1-Enyl]cyclopentyl}-N-Ethylhept-5-Enamide;(5z)-7-{(1r,2r,3r,5s)-3,5-Dihydroxy-2-[(1e,3s)-3-Hydroxy-5-Phenylpent-1-Enyl]cyclopentyl}-N-Ethylhept-5-Enamide;BIMATOPROST [VANDF];BIMATOPROST [VANDF];AS-35082;AS-35082;CHEMBL1200963;CHEMBL1200963;LS-181817;LS-181817;Latisse (TN);Latisse (TN);1ST159263;1ST159263;bimatoprostum;bimatoprostum;BIMATOPROST (MART.);BIMATOPROST (MART.);Bimatoprost in bulk;Bimatoprost in bulk;SR-01000942224-1;SR-01000942224-1;5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-, (5Z)-;5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-, (5Z)-;QXS94885MZ;QXS94885MZ;GANFORT COMPONENT BIMATOPROST;GANFORT COMPONENT BIMATOPROST;DB00905;DB00905;Latisse;Latisse;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide;DTXSID30895042;DTXSID30895042;BIMATOPROST [EMA EPAR];BIMATOPROST [EMA EPAR];GTPL1958;GTPL1958;EN300-21680860;Bimatoprost;EN300-21680860;BIMATOPROST [USAN];Bimatoprost;Lumigan;BIMATOPROST [USAN];Lumigan;17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide, >=95%, solid;17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide, >=95%, solid;5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-;5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-;(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-pheny... |